Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.235 USD | +9.29% | +4.53% | +82.49% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+82.49% | 554M | |
+68.60% | 62.86B | |
-1.04% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.15% | 26.46B | |
-22.09% | 18.9B | |
+4.29% | 12.67B | |
+24.15% | 12.27B | |
+28.51% | 12.07B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Truist Securities Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Maintains Buy Rating